Stockscreener 앱 받기
8.86
2.67%
0.23
전일 마감가:
$8.63
열려 있는:
$8.6
하루 거래량:
2.86M
Relative Volume:
0.90
시가총액:
$1.19B
수익:
$24.30M
순이익/손실:
$-145.57M
주가수익비율:
-6.6617
EPS:
-1.33
순현금흐름:
$-149.17M
1주 성능:
+1.84%
1개월 성능:
-18.79%
6개월 성능:
+73.05%
1년 성능:
+186.73%
1일 변동 폭
$8.55
$8.925
1주일 범위
$8.45
$9.00
52주 변동 폭
$1.03
$11.20
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
TNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
8.86 | 1.16B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics (NASDAQ:TNGX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq index Notes Liquidity Move - Kalkine Media
Tango Therapeutics Advances TNG462 Study for MTAP-deleted Tumors - MSN
Patterns Watch: How Tango Therapeutics Inc stock reacts to oil pricesDip Buying & Safe Entry Point Identification - moha.gov.vn
Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why - MSN
3 Stocks With Strong Upside Potential for 2026 Gains - Tokenist
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026 - Investing.com
Certain Common Stock of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Pre-Funded Warrants of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - WV News
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Tango Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Sentiment & Fast Entry High Yield Tips - Улправда
Will Tango Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Trends & AI Driven Stock Reports - Улправда
Why Tango Therapeutics Inc. stock remains a top recommendationMarket Trend Report & Technical Pattern Based Signals - DonanımHaber
Will Tango Therapeutics Inc. stock deliver strong dividend growthProduct Launch & Real-Time Volume Analysis - DonanımHaber
Can Tango Therapeutics Inc. stock sustain market leadershipDay Trade & Verified Swing Trading Watchlist - DonanımHaber
Can Tango Therapeutics Inc. stock reach $100 price target2025 Sector Review & High Accuracy Swing Entry Alerts - Улправда
5 Biotech Stocks to Watch for Potential Upside - The Globe and Mail
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 7.6%Here's What Happened - MarketBeat
Tango Therapeutics Earnings Notes - Trefis
Is Tango Therapeutics (TNGX) Overvalued After a 200% One-Year Surge? A Fresh Look at Its Pricing - Yahoo Finance
Highs Report: Is Tango Therapeutics Inc stock a defensive play in 2025Portfolio Performance Report & Risk Managed Investment Signals - moha.gov.vn
Tango Therapeutics (NASDAQ:TNGX) Raised to Buy at Wall Street Zen - MarketBeat
Stempoint Capital LP Acquires Shares of 208,800 Tango Therapeutics, Inc. $TNGX - MarketBeat
Can Tango Therapeutics (TNGX) climb 37.28% to reach the level Wall Street analysts expect? - MSN
Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 4.6%Should You Sell? - MarketBeat
Vivo Capital LLC Purchases Shares of 600,000 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by XTX Topco Ltd - MarketBeat
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect? - Finviz
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32% - simplywall.st
Geode Capital Management LLC Grows Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
How interest rate cuts could boost Tango Therapeutics Inc. stockMarket Risk Analysis & Daily Profit Focused Screening - Newser
Stifel Initiates Coverage of Tango Therapeutics (TNGX) with Buy Recommendation - Nasdaq
Is Tango Therapeutics Inc. stock near bottom after declineJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target - Investing.com Nigeria
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target By Investing.com - Investing.com South Africa
Piper Sandler Healthcare Conference - marketscreener.com
Virtus Investment Advisers LLC Sells 38,979 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (TNGX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can Tango Therapeutics Stock Hold Up When Markets Turn? - Trefis
Retail Trends: How interest rate cuts could boost Tango Therapeutics Inc stockRecession Risk & Fast Exit Strategy with Risk Control - moha.gov.vn
Tango Therapeutics Inc trading resumes - MSN
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy - MSN
Tango Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
자본화:
|
볼륨(24시간):